HomeIndustriesHealthcareNovocure CEO on Fighting Aggressive Cancers, Treatment Development Pipeline

Novocure CEO on Fighting Aggressive Cancers, Treatment Development Pipeline

Ashley Cordova, CEO of Novocure (NVCR), joins Trading 360 after ringing the opening bell at the Nasdaq. Novocure “targets the electrical properties of cells” to fight aggressive cancers. “We are focused on extending survival,” she says, and notes recent FDA approval for lung cancer treatment and clinical trials in pancreatic and brain cancers. She also discusses the company’s balance sheet, R&D investment, and potential partnerships.

Trading 360

10 Feb 2025

SHARE

ON AIR
education
1:00 pm
Liz Ann Live
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
education
5:00 am
Liz Ann Live
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Market Overtime
REPLAY
8:00 am
Market Overtime
REPLAY
8:30 am
Market On Close
REPLAY
education
10:00 am
Schwab 2026 Outlook
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
ON AIR
education
1:00 pm
Liz Ann Live
REPLAY
1:30 pm
The Wrap
REPLAY
3:00 pm
Market Overtime
REPLAY
4:00 pm
Market Overtime
REPLAY
4:30 pm
Market On Close
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Fast Market
REPLAY
8:00 pm
Next Gen Investing
REPLAY
education
9:00 pm
Liz Ann Live
REPLAY
9:30 pm
The Wrap
REPLAY
11:00 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor